Table 5.
Five-year overall survival (OS) and relative survival (RS) estimates (95% confidence interval) for myeloid malignancies: Haematological Malignancy Research Network diagnoses Sept 2004 to Aug 2013, followed through to September 2015.
| Total diagnoses |
Males |
Females |
||||
|---|---|---|---|---|---|---|
| OS (95% CI) | RS (95% CI) | OS (95% CI) | RS (95% CI) | OS (95% CI) | RS (95% CI) | |
| All myeloid malignancies | 40.3 (38.9–41.7) | 51.2 (49.5–52.9) | 38 (36.0–40.0) | 48.8 (46.3–51.2) | 48.2 (45.9–50.4) | 60.4 (57.7–62.9) |
| Acute myeloid leukaemia | 12.9 (11.3–14.7) | 14.7 (12.9–16.7) | 12.8 (10.6–15.2) | 14.7 (12.2–17.4) | 13.3 (10.9–15.9) | 14.9 (12.3–17.9) |
| AML, not otherwise specified | 8.2 (6.6–10.0) | 9.5 (7.7–11.7) | 8.8 (6.5–11.4) | 10.2 (7.6–13.3) | 7.4 (5.2–9.9) | 8.7 (6.2–11.7) |
| AML with myelodysplasia-related changes | 2.8 (1.3–5.4) | 3.1 (1.4–5.9) | 1.8 (0.5–4.6) | 2.0 (0.6–5.0) | 4.6 (1.6–10.4) | 4.9 (1.6–11.1) |
| AML with NPM mutation | 22.2 (14.5–30.9) | 25.0 (16.3–34.6) | 25.3 (13.1–39.4) | 29.0 (14.8–44.8) | 21.0 (11.8–32.0) | 23.4 (13.1–35.5) |
| Acute promyelocytic leukaemia | 58.6 (47.0–68.4) | 61.7 (49.4–71.9) | 55.3 (38.8–69.0) | 59.7 (41.4–74.0) | 61.4 (44.5–74.6) | 62.9 (45.4–76.2) |
| AML, core binding factor | 55.3 (42.0–66.7) | 57.1 (43.3–68.7) | 50.0 (33.5–64.3) | 51.2 (34.3–65.8) | 64.3 (41.2–80.3) | 66.8 (42.2–82.8) |
| AML, probable therapy related | 2.4 (0.4–8.3) | 2.6 (0.4–9.0) | 5.2 (0.9–15.5) | 5.80 (1.0–17.0) | 1.1 (0.0–8.9) | 1.2 (0.0–9.2) |
| AML with MLL (11q23) | 31.1 (14.0–50.0) | 31.4 (14.1–50.4) | 46.7 (16.0–72.9) | 47.1 (16.0–73.4) | 22.8 (5.9–46.3) | 22.9 (5.9–46.5) |
| Myelodysplastic syndromes (MDS) | 21.2 (18.7–23.8) | 28.1 (24.9–31.5) | 19.2 (16.2–22.4) | 25.5 (21.5–29.7) | 24.8 (20.3–29.6) | 32.0 (26.1–37.9) |
| Refractory cytopenia with multilineage dysplasia | 23.1 (19.1–27.3) | 31.1 (25.7–36.6) | 21.2 (16.6–26.2) | 28.4 (22.2–35.0) | 27.3 (19.3–36) | 36.4 (25.6–47.2) |
| Refractory anaemia with excess blasts | 7.9 (5.5–10.9) | 9.9 (6.9–13.6) | 7.6 (4.5–11.8) | 9.8 (5.7–15.1) | 8.4 (4.6–13.8) | 10.2 (5.5–16.6) |
| Refractory anaemia with ring sideroblasts | 41.3 (34.2–48.3) | 57.2 (47.1–66) | 37.5 (28.6–46.3) | 51.6 (39–62.8) | 47.8 (35.0–59.5) | 62.8 (45.0–76.2) |
| Myelodysplastic syndrome(5q-) | 53.7 (31.6–71.4) | 68.7 (35.6–87.3) | 23.8 (0.8–65.5) | 29.4 (0.6–74.7) | 56.4 (31.1–75.5) | 72.5 (31.9–91.4) |
| Myeloproliferative neoplasms (MPN) | 69.7 (67.7–71.7) | 89.3 (86.9–91.3) | 68.0 (64.8–70.9) | 87.6 (83.8–90.5) | 73.2 (70.3–75.9) | 92.8 (89.4–95.2) |
| Chronic MPNsb | 71.5 (69.2–73.7) | 93.1 (90.2–95.1) | 70.0 (66.3–73.3) | 93.9 (88.5–96.8) | 73.8 (70.6–76.7) | 94.3 (90.2–96.7) |
| Chronic myeloid leukaemia | 77.7 (72.3–82.2) | 89.8 (84.0–93.6) | 78.3 (71.0–84.0) | 88.7 (80.4–93.6) | 77.0 (67.6–84.0) | 92.1 (78.4–97.2) |
| Myelofibrosis | 32.1 (24.2–40.2) | 42.0 (31.5–52.1) | 25.7 (16.3–36.3) | 32.8 (20.5–45.7) | 44.9 (28.3–60.2) | 59.7 (35.8–77.1) |
| Systemic mastocytosis | 79.8 (57.9–91.1) | 88.7 (53.2–97.8) | 59.5 (19.8–84.7) | 62.9 (19.1–87.8) | 87.9 (59.5–96.9) | 95.5 (10.8–99.9) |
| MDS/MPN | 13.0 (9.1–17.6) | 17.4 (12.1–23.5) | 9.4 (5.1–15.3) | 12.6 (6.8–20.2) | 19.7 (11.2–29.9) | 26.8 (15.1–39.9) |
| Chronic myelomonocytic leukaemia | 13.3 (9.1–18.4) | 18.1 (12.3–24.8) | 10.6 (5.7–17.4) | 14.3 (7.5–23.1) | 19.5 (10.6–30.5) | 27.0 (14.4–41.3) |
| MDS/MPN, unclassifiedb | 0 | 0 | 0 | 0 | 0 | 0 |
| Atypical chronic myeloid leukaemia | 0.2 (0.0–11.0) | 0.2 (0.0–12.5) | 0.1 (0.0–8.1) | 0.1 (0.0–9.2) | 17.4 (1.1–50.6) | 18.5 (1.1–53.0) |
aPolycythaemia vera, essential thrombocythaemia, MPNs unclassified.
b
All 23 patients died within 5 years of diagnosis.